Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma

彭布罗利珠单抗 医学 肿瘤科 内科学 头颈部鳞状细胞癌 头颈部癌 队列 人口 癌症 免疫疗法 环境卫生
作者
Chris Black,Glenn J. Hanna,Liya Wang,Karthik Ramakrishnan,Daisuke Goto,Vladimir Turzhitsky,Gleicy M. Hair
出处
期刊:Frontiers in Oncology [Frontiers Media SA]
卷期号:13 被引量:2
标识
DOI:10.3389/fonc.2023.1160144
摘要

Background Pembrolizumab, a PD-1 immune checkpoint inhibitor, is approved as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) as monotherapy or in combination with platinum and 5-fluorouracil chemotherapy. Limited data exist on the use of these regimens in real-world settings. Objective Our primary objectives were to describe baseline characteristics and real-world overall survival (rwOS), time on treatment (rwToT), and time to next treatment (rwTTNT) among individuals with R/M HNSCC receiving approved 1L pembrolizumab therapies. We also aimed to identify baseline factors associated with choice of 1L pembrolizumab therapy and with rwOS. Methods This was a retrospective cohort study of adults with R/M HNSCC receiving 1L pembrolizumab monotherapy or pembrolizumab plus chemotherapy. We used Kaplan-Meier analyses to assess real-world outcomes, logistic regression modeling to identify factors associated with choice of 1L pembrolizumab therapy, and Cox proportional hazards models to identify factors associated with rwOS. Results The study population included 431 individuals receiving 1L pembrolizumab monotherapy and 215 receiving 1L pembrolizumab plus chemotherapy. The use of 1L pembrolizumab monotherapy was associated with higher baseline combined positive score for PD-L1 expression, older age, higher Eastern Cooperative Oncology Group performance status (ECOG PS), laryngeal tumor site, and human papillomavirus (HPV)-positive tumor status. The pembrolizumab monotherapy group had a median (95% CI) rwOS of 12.1 (9.2–15.1) months, rwToT of 4.2 (3.5–4.6) months, and rwTTNT of 6.5 (5.4–7.4) months. Among this group, HPV-positive tumor status and lower ECOG PS were associated with longer rwOS, and oral cavity tumor site with shorter rwOS. The pembrolizumab plus chemotherapy cohort had a median (95% CI) rwOS of 11.9 (9.0–16.0) months, rwToT of 4.9 (3.8–5.6) months, and rwTTNT of 6.6 (5.8–8.3) months. In this group, HPV-positive tumor status was associated with longer rwOS. Conclusions This study adds to clinical trial data by summarizing real-world treatment outcomes with 1L pembrolizumab-containing therapies in a more heterogeneous population. Overall survival outcomes in both treatment groups were similar to those observed in the registration clinical trial. These findings support the use of pembrolizumab as standard of care for R/M HNSCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
oi完成签到,获得积分10
刚刚
jin发布了新的文献求助10
1秒前
1秒前
1秒前
2秒前
濮阳冰海完成签到 ,获得积分10
2秒前
xl²-B完成签到,获得积分10
3秒前
董董完成签到,获得积分20
3秒前
彭珊发布了新的文献求助10
4秒前
4秒前
12等等发布了新的文献求助10
4秒前
胖仔发布了新的文献求助10
5秒前
程志杰应助restudy68采纳,获得10
5秒前
Guochunbao完成签到,获得积分10
6秒前
Lucas应助xiongyh10采纳,获得10
6秒前
暖部完成签到,获得积分10
6秒前
大模型应助聪明球球采纳,获得10
7秒前
大方的依琴完成签到,获得积分10
8秒前
9秒前
ding应助大有阳光采纳,获得10
9秒前
10秒前
董董发布了新的文献求助10
11秒前
平常的可乐完成签到 ,获得积分10
13秒前
14秒前
yjl发布了新的文献求助10
15秒前
鲜于雁易完成签到,获得积分10
15秒前
杨然发布了新的文献求助10
15秒前
12等等完成签到,获得积分10
15秒前
16秒前
16秒前
16秒前
17秒前
云中子发布了新的文献求助10
18秒前
卓矢发布了新的文献求助10
19秒前
19秒前
大有阳光发布了新的文献求助10
20秒前
万能图书馆应助Rita采纳,获得10
20秒前
难过冷玉完成签到,获得积分10
21秒前
23秒前
24秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Saponins and sapogenins. IX. Saponins and sapogenins of Luffa aegyptica mill seeds (black variety) 500
Fundamentals of Dispersed Multiphase Flows 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3260778
求助须知:如何正确求助?哪些是违规求助? 2901898
关于积分的说明 8317946
捐赠科研通 2571648
什么是DOI,文献DOI怎么找? 1397111
科研通“疑难数据库(出版商)”最低求助积分说明 653655
邀请新用户注册赠送积分活动 632178